However, the cases in this study were required to strictly fulfill the 2015 IPND criteria, and thus only those with an NMO phenotype were analyzed (The prevalence of MOG-antibody-positive NMO was calculated to be 0.11/100,000). This evidence concerns the gene MOG and neuromyelitis optica.